World Journal of Urology

, Volume 29, Issue 1, pp 51–57 | Cite as

Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity

  • Priya Padmanabhan
  • Harriette M. Scarpero
  • Douglas F. Milam
  • Roger R. Dmochowski
  • David F. Penson
Topic Paper

Abstract

Purpose

Treatment options for antimuscarinic refractory neurogenic detrusor overactivity (NDO) are botulinum toxin type A injections (BTX-A) and augmentation cystoplasty (AC). We estimated initial and cumulative 5-year costs of these treatments.

Materials and methods

Base case is an individual with antimuscarinic refractory NDO and decreased bladder compliance. Primary analysis is from the health care payor perspective. Model probabilities and ranges were derived from literature and chart review. Reimbursements were derived from the average of insurance carriers. Complication cost calculations were based on standard practice. Decision-analysis model was made with TreeAge Pro Healthcare 2009 Software, Inc. and rolled back for cost calculation. One-way sensitivity analysis was performed on all variables, and two-way sensitivity analyses were based on these results.

Results

Average reimbursement for one BTX-A injection and AC was $2,946.83 and $25,041.53, respectively. BTX-A treatment was less expensive over 5 years, costing $28,065. The model was only sensitive within a reasonable clinical range for Botox durability. BTX-A was more cost-effective over 5 years if the effect lasted for >5.1 months. The model was based on an AC complication rate of 40%. If the PAC complication rate < 14%, AC was cheaper over 5 years. The model was sensitive to surgeons costs of BTX-A ($3,027) and facility costs of BTX-A ($1,004) and AC ($17,100).

Conclusions

This is the first cost analysis of BTX-A and AC. BTX-A is cheaper at durations >5.1 months and AC was cheaper when the cost of BTX-A increases or the AC complication rate dropped below 14%.

Keywords

Neurogenic bladder Overactive detrusor Botulinum toxin type A Economics 

References

  1. 1.
    Herschorn S, Hewitt RJ (1998) Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder. Urology 52:672CrossRefPubMedGoogle Scholar
  2. 2.
    Stohrer M, Schurch B, Kramer G et al (1999) Botulinum A-toxin in the treatment of detrusor hyperreflexia in spinal cord injured patients: a new alternative to medical and surgical procedures? Neurourol Urodyn 18:401CrossRefGoogle Scholar
  3. 3.
    Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510CrossRefPubMedGoogle Scholar
  4. 4.
    Karsenty G, Reitz A, Lindemann G et al (2006) Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 68:1193CrossRefPubMedGoogle Scholar
  5. 5.
    Apostolidis A, Jacques TS, Freeman A et al (2008) Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 53:1245CrossRefPubMedGoogle Scholar
  6. 6.
    Kalsi V, Popat RB, Apostolidis A et al (2006) Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49:519CrossRefPubMedGoogle Scholar
  7. 7.
    Boy S, Seif C, Braun P (2008) Retrospective analysis of treatment outcomes and medical care of patients with neurogenic detrusor overactivity (NDO) receiving BOTOX therapy. Eur Urol Suppl 7:212CrossRefGoogle Scholar
  8. 8.
    Del Popolo G, Li Marzi V, Lombardi G (2004) Efficacy, safety and dosage of English botulinum toxin-A in neurogenic detrusor overactivity. Eur Urol 3:A663Google Scholar
  9. 9.
    Del Popolo G, Filocamo MT, Li Marzi V et al (2008) Neurogenic detrusor overactivity treated with English botulinum toxin a: 8-year experience of one single centre. Eur Urol 53:1013CrossRefPubMedGoogle Scholar
  10. 10.
    Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47:653CrossRefPubMedGoogle Scholar
  11. 11.
    Reitz A, Denys P, Fermanian C et al (2007) Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 52:1729CrossRefPubMedGoogle Scholar
  12. 12.
    Chenet A, Perrouin-Verbe B, Le Normand L et al (2007) Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity. Ann Readapt Med Phys 50:651PubMedGoogle Scholar
  13. 13.
    Giannantoni A, Mearini E, Del Zingaro M et al (2009) Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 55:705CrossRefPubMedGoogle Scholar
  14. 14.
    Karsenty G, Denys P, Amarenco G et al (2008) Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53:275CrossRefPubMedGoogle Scholar
  15. 15.
    Schurch B, de Seze M, Denys P et al (2005) Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174:196CrossRefPubMedGoogle Scholar
  16. 16.
    Giannantoni A, Mearini E, Di Stasi SM et al (2004) New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56:79PubMedGoogle Scholar
  17. 17.
    Bagi P, Biering-Sorensen F (2004) Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38:495CrossRefPubMedGoogle Scholar
  18. 18.
    Schurch B, Stohrer M, Kramer G et al (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692CrossRefPubMedGoogle Scholar
  19. 19.
    Schulte-Baukloh H, Schobert J, Stolze T et al (2006) Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 25:110CrossRefPubMedGoogle Scholar
  20. 20.
    Kalsi V, Apostolidis A, Popat R et al (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49:528CrossRefPubMedGoogle Scholar
  21. 21.
    Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63:868CrossRefPubMedGoogle Scholar
  22. 22.
    Klaphajone J, Kitisomprayoonkul W, Sriplakit S (2005) Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch Phys Med Rehabil 86:2114CrossRefPubMedGoogle Scholar
  23. 23.
    Kennelly M, Kang J (2003) Botulinum-A toxin injections as a treatment for refractory detrusor hyperreflexia. Top Spinal Cord in J Rehabil 8:46CrossRefGoogle Scholar
  24. 24.
    Pannek J, Gocking K, Bersch U (2009) Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. BJU Int 104:1246CrossRefPubMedGoogle Scholar
  25. 25.
    Freedman ER, Singh G, Donnell SC et al (1994) Combined bladder neck suspension and augmentation cystoplasty for neuropathic incontinence in female patients. Br J Urol 73:621CrossRefPubMedGoogle Scholar
  26. 26.
    Blyth B, Ewalt DH, Duckett JW et al (1992) Lithogenic properties of enterocystoplasty. J Urol 148:575PubMedGoogle Scholar
  27. 27.
    Rink RC (1999) Bladder augmentation. Options, outcomes, future. Urol Clin North Am 26:111CrossRefPubMedGoogle Scholar
  28. 28.
    Greenwell TJ, Venn SN, Mundy AR (2001) Augmentation cystoplasty. BJU Int 88:511CrossRefPubMedGoogle Scholar
  29. 29.
    Chartier-Kastler EJ, Mongiat-Artus P, Bitker MO et al (2000) Long-term results of augmentation cystoplasty in spinal cord injury patients. Spinal Cord 38:490CrossRefPubMedGoogle Scholar
  30. 30.
    Gough DC (2001) Enterocystoplasty. BJU Int 88:739CrossRefPubMedGoogle Scholar
  31. 31.
    Zachoval R, Pitha J, Medova E et al (2003) Augmentation cystoplasty in patients with multiple sclerosis. Urol Int 70:21CrossRefPubMedGoogle Scholar
  32. 32.
    Game X, Castel-Lacanal E, Bentaleb Y et al (2008) Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol 53:613CrossRefPubMedGoogle Scholar
  33. 33.
    Chancellor MB (2009) Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int Urol NephrolGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Priya Padmanabhan
    • 1
  • Harriette M. Scarpero
    • 1
  • Douglas F. Milam
    • 1
  • Roger R. Dmochowski
    • 1
  • David F. Penson
    • 1
  1. 1.Department of Urologic SurgeryVanderbilt UniversityNashvilleUSA

Personalised recommendations